

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Gerst Diane G.					Amphastar Pharmaceuticals, Inc. [AMPH]							ŀ	_X_ Director		10%	6 Owner	
(Last)	(Last) (First) (Middle)				3. Date of Earliest Transaction (MM/DD/YYYY)							-	Officer (give title below) Other (specify below)				pelow)
C/O AMPHA PHARMAC 6TH STREE	EUTICA	LS, INC	E., 11570)			6/5	5/202	23								
(Street)				4. I:	4. If Amendment, Date Original Filed (MM/DD/YYYY)						6. Individual or Joint/Group Filing (Check Applicable Line)						
RANCHO CUCAMONGA, CA 91730												X _ Form filed by One Reporting Person Form filed by More than One Reporting Person					
,	ity) (Sta		Table I -	that	Chect is in	ck this b	to satisfy	icate the a	that a	a transac native de isposed	of, or Bo	ndi	ade pursuant to tions of Rule 1	10b5-1(c).	See Instruc	tion 10.	
1. Title of Security (Instr. 3)				Exect		3. Trans. Co (Instr. 8)	or I		curities Ac sposed of (. 3, 4 and 5	D) Fo		. Amount of Securities Beneficially Owned ollowing Reported Transaction(s) Instr. 3 and 4)		6. Ownership Form: Direct (D) or Indirect	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code		Code	V Ame		unt (A)						(I) (Instr. 4)	(IIIsu. 4)
Common Stock 6/5/202				6/5/2023	A 2716 (1) A \$0.00 15558			D									
	Tab	ole II - Der	ivative Se	ecurities I	Bene	eficially	Owned (e.g., _I	puts,	calls, w	arrants	, op	otions, conver	tible secu	rities)		
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed Execution Date, if any	Code	Derivative		Securities (A) or of (D)	6. Date Exercisable and Expiration Date			7. Title and A Securities Un Derivative S (Instr. 3 and		derlying Derivative Security Security	9. Number of derivative Securities Beneficially Owned Following		11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exerci	isable	Expiration Date	¹ Title		Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect	
Stock Option (right to buy)	\$46.01	6/5/2023		A		7016		(2	2).	6/5/2031	Commo Stock	n	7016	\$0	7016	D	

Explanation of Responses:

- (1) The reported shares are represented by restricted stock units, or RSUs, all of which vest on June 5, 2024.
- (2) All of the shares subject to the option vest on June 5, 2024.

Reporting Owners

Reporting Owner Name / Address	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Gerst Diane G.						
C/O AMPHASTAR PHARMACEUTICALS, INC.	X					
11570 6TH STREET	21					
RANCHO CUCAMONGA, CA 91730						

Signatures

/s/ Eva Wen, by power of attorney	6/7/2023
**Signature of Reporting Person	Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.